An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006

Epidemiology and Infection

Volumn 138, Issue 9, 2010, Pages 1281-1288

  Fleming, D M ^a   Verlander, N Q ^b   Elliot, A J ^a,b   Zhao, H ^a   Gelb, D ^a   Jehring, D ^c   Nguyen Van Tam, J S ^d  

^a ROYAL COLLEGE OF GENERAL PRACTITIONERS   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c Apollo Medical Systems Ltd   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Acute respiratory infections; infectious disease control; influenza; statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRONCHITIS; CONTROLLED STUDY; DRUG USE; ELECTRONIC MEDICAL RECORD; FEMALE; GENERAL PRACTITIONER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFLUENZA VACCINATION; MALE; MORBIDITY; PNEUMONIA; PRIMARY MEDICAL CARE; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME; UNITED KINGDOM; URINARY TRACT INFECTION; WINTER; ACUTE DISEASE; MEDICAL RECORD; MIDDLE AGED; PRIMARY HEALTH CARE; RETROSPECTIVE STUDY; SEASON; STATISTICAL MODEL;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ELECTRONIC HEALTH RECORDS; ENGLAND; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; INFLUENZA VACCINES; LOGISTIC MODELS; MALE; MIDDLE AGED; MORBIDITY; PNEUMOCOCCAL VACCINES; PRIMARY HEALTH CARE; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; SEASONS;

EID: 77956636977     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268810000105     Document Type: Article

References (36)

1. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nature Reviews Drug Discovery 2005;4:977-987.
2. Baigent C, et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
3. Fedson DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clinical Infectious Diseases 2006;43:199-205.
4. Alegret M, Silvestre JS. Pleiotropic effects of statins and related pharmacological experimental approaches. Methods & Findings in Experimental & Clinical Pharmacology 2006;28:627-656.
5. Blanco-Colio LM, et al. Anti-inflammatory and immunomodulatory effects of statins. Kidney International 2003;63:12-23.
6. Novack V, Terblanche M, Almog Y. Do statins have a role in preventing or treating sepsis? Critical Care 2006;10:113.
7. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004;109(21 Suppl. 1): II18-II26.
8. Colhoun HM, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696.
9. Collins R, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-767.
10. Almog Y. Statins, inflammation, and sepsis: hypothesis. Chest 2003;124:740-743.
11. Almog Y, et al. The effect of statin therapy on infectionrelated mortality in patients with atherosclerotic diseases. Critical Care Medicine 2007;35:372-378.
12. Almog Y, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004;110:880-885.
13. Liappis AP, et al. The effect of statins on mortality in patients with bacteremia. Clinical Infectious Diseases 2001;33:1352-1357.
14. Cheung CY, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002;360:1831-1837.
15. Frost FJ, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131:1006-1012.
16. Majumdar SR, et al. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. British Medical Journal 2006;333:999.
17. Mortensen EM, et al. The effect of prior statin use on 30-day mortality for patients hospitalized with communityacquired pneumonia. Respiratory Research 2005;6:82.
18. Schlienger RG, et al. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007;27:325-332.
19. van de Garde EM, et al. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006;61:957-961.
20. Smeeth L, et al. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. British Journal of Clinical Pharmacology 2009;67:99-109.
21. Fleming DM. Weekly Returns Service of the Royal College of General Practitioners. Communicable Disease and Public Health 1999;2:96-100.
22. Chisholm J. The Read clinical classification. British Medical Journal 1990;300:1092.
23. Fleming DM, Elliot AJ. Lessons from 40 years" surveillance of influenza in England and Wales. Epidemiology and Infection 2008;136:866-875.
24. StataCorp. Intercooled Stata version 10. College Station, TX, USA: Stata Corporation, 2007.
25. Fleming DM, et al. Respiratory illness associated with influenza and respiratory syncytial virus infection. Archives of Diseases in Childhood 2005;90:741-746.
26. Hall SA, et al. The relationship of common medical conditions and medication use with symptoms of painful bladder syndrome: results from the Boston area community health survey. Journal of Urology 2008;180:593-598.
27. Packard RR, et al. Atorvastatin treatment and vaccination efficacy. Journal of Clinical Pharmacology 2007;47:1022-1027.
28. Hak E, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clinical Infectious Diseases 2002;35:370-377.
29. Jackson LA, et al. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. International Journal of Epidemiology 2006;35:337-344.
30. Simonsen L, et al. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infectious Diseases 2007;7:658-666.
31. Greenland S, Lash TL. Bias analysis. In: Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology, 3rd edn. Philadelphia, PA: Lippincott, Williams & Wilkins, 2008, pp. 345-380.
32. Fleming DM, Cross KW, Pannell RS. Influenza and its relationship to circulatory disorders. Epidemiology and Infection 2005;133:255-262.
33. Nichol KL, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. New England Journal of Medicine 2003;348:1322-1332.
34. Verel D, Ward C, Rickards DF. Proceedings: Electrocardiographic changes in A2 England-42-72 influenza infection in patients treated at home. British Heart Journal 1974;36:395.
35. Verel D, et al. Observations on the A2 England influenza epidemic: a clinicopathological study. American Heart Journal 1976;92:290-296.
36. Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine 2008;359:2195-2207.